Abstract: The American Psychiatric Associations Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) defines insomnia as a complaint regarding the quantity, quality, or sleep timing at least 3 times a week for at least 1 month. In spite of presence of several treatment modalities, it possesses significant challenge in the development of effective treatment protocol of insomnia. The varied presentation of the disorder as well as uncertainty in efficacy and safety profile of treating agents complicates the scenario for physicians. There is an unmet medical need to develop an effective yet safe treatment option to address these multiple factors contributing to several aspects of insomnia. Materials and Methods: Twenty four subjects, diagnosed as case of insomnia as per The American Psychiatric Associations Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Guidelines were enrolled in case study. Nine subjects who completed the study were assessed to evaluate efficacy of the proprietary formulation E-IN-05 on improving the sleep quality; Sleep Onset Latency; Sleep Efficiency; Sleep Duration and Day Enthusiasm level. Result: Six weeks administration of E-IN-05 yielded an overall improvement. The mean sleep quality improved from 2.4 (0.52) on Day-0 to 0.89(0.78) on Day-42.Sleep efficiency increased to 69.48(. 9.22)Day-42 as compared to that of 46.6(10.76) on Day-0. The mean sleep latency reduced from 81.1(18.83) mins at Day 0 to 40(14.79) mins at Day 42.The initial sleep duration score of 3(0) at Day 0 gradually improved to 1.78(1.3) at Day 42. The mean enthusiasm level in the study population on Day – 0 was calculated as 0.66 (0.5) which increased to 2.22 (0.97)at the end of the study. Conclusion: Six weeks administration of E-IN-05 yielded a significant improvement in several aspects of Pittsburgh Sleep Quality Index score namely Sleep quality, Sleep efficiency, sleep latency and day enthusiasm level.